Psoriasis Therapeutics Pipeline Analysis 2017

  • ID: 4435239
  • Report
  • 301 pages
  • P&S Market Research
1 of 3
Psoriasis Therapeutics Pipeline in 2017:

The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of the skin, causing patches of psoriasis to appear. There are five types of psoriasis namely, plaque psoriasis or psoriasis vulgaris, guttate psoriasis, inverse psoriasis or flexural psoriasis or intertriginous psoriasis, pustular psoriasis, and erythrodermic or exfoliative psoriasis.

Insights on Pipeline Segments:

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by topical route.

PAD technology platform for psoriasis drug development:

MC2 Therapeutics A/S is using PAD technology platform for the development of MC2-01 for the treatment of psoriasis. PAD technology platform offers a number of unique advantages in the development of new topical drugs. PAD vehicles are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a thin yet robust aqueous film of surfactants.

Various collaborations for psoriasis drug development:

Boehringer Ingelheim GmbH and AbbVie, Inc. entered in a worldwide agreement to develop and commercialize BI 655066, for the treatment of psoriasis.
Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.

Psoriasis Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Molecule Type
1.3.3. Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By industry participants
2.2.1.2. By company type

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.1.1 Signs and Symptoms
4.1.2 PAThophysiology
4.1.3 Epidemiology
4.1.4 Diagnosis
4.1.5 Treatment
4.2 Key Drivers
4.3 Key Barriers
4.4 Psoriasis Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

5. Psoriasis Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase II: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Phase I: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Pre-Clinical: Drug profiles
5.6 Discovery: Drug profiles
5.7 Unknown: Drug profiles

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for Psoriasis Therapeutics Pipeline
7.2 SWOT Analysis of Psoriasis Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables:

Pipeline Analysis Of Psoriasis Therapeutics, By Company (2017)
Description Of Filed Drug Candidates
Clinical Trials Of Filed Drug Candidates
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Description Of Unknown Drug Candidates
Companies- At A Glance

List of Figures:

Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research By Industry Participant
Breakdown Of Primary Research By Company Type
PAThophysiology Of Psoriasis
Psoriasis Therapeutics Drug Candidates Under Development (2017)
Psoriasis Therapeutics Pipeline Split, By Molecule Type (2017)
Psoriasis Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking For Psoriasis Therapeutics Pipeline
SWOT Analysis Of Psoriasis Therapeutics Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll